Medtronic's Hugo Robot Gets US Approval
Medtronic's Hugo robotic-assisted surgery platform is now FDA approved in the United States. This is a big deal because about 90% of global robotic surgeries happen in the U.S., positioning Medtronic to directly compete with Intuitive Surgical and Johnson & Johnson. Medtronic emphasizes its unique position as an OEM offering both open and robotic surgery solutions.
The FDA clearance is for urologic surgical procedures, including prostatectomy, nephrectomy, and cystectomy, which account for approximately 230,000 surgeries annually in the U.S.. Medtronic plans to expand Hugo's use to other specialties like general surgery and gynecology. The Hugo system features independent robotic arms on wheeled carts for portability and modularity, and integrates with Medtronic's Touch Surgery digital platforms, offering AI and video education for clinicians. Medtronic's Hugo aims to compete with Intuitive Surgical's da Vinci system, which has dominated the robotic surgery market for over two decades. While analysts note similarities between Hugo and da Vinci, Medtronic highlights Hugo's unique features like its open console for better communication with surgical staff and potential cost advantages. The surgical robotics market is projected to reach $9.2 billion by 2034, with Intuitive Surgical currently holding nearly 60% of the global market share. Hugo is about 20% to 25% cheaper than the da Vinci system. Medtronic is focusing on training and support to build a loyal customer base for Hugo. The company aims to gain market share by offering a competitive option and expanding access to robotic surgery.
